Company news

TuHURA Biosciences, Inc. news in 2026

TuHURA Biosciences, Inc.'s news releases, calls and decks from 2026, newest first.

View company

TuHURA Biosciences Reports Third Quarter 2026 Financial Results and Provides a Corporate Update

November 13, 2026

TuHURA Biosciences Announces Three Presentations at the 68th American Society of Hematology Annual Meeting and Exposition

November 4, 2026

TuHURA Biosciences Provides First Look at Data from its Open-Label Study of IFx-2.0 as an Adjunctive Therapy to Keytruda® in First Line Treatment of Patients with Deep Seated Metastatic Merkel Cell Carcinoma

October 26, 2026

TuHURA Biosciences Receives New U.S. Patent Broadening Coverage for its VISTA Inhibitor, TBS-2025

October 13, 2026

TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology

October 5, 2026

TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood-Related Cancers

September 14, 2026

TuHURA Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference

September 8, 2026

TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

August 14, 2026

TuHURA Biosciences to Present at Canaccord Genuity's 46th Annual Growth Conference

July 22, 2026

TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers

June 15, 2026

TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update

May 15, 2026

TuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference

May 12, 2026

TuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into 2028

April 21, 2026

TuHURA Biosciences Appoints Amanda Garofalo, MSHS, as Senior Vice President of Clinical Operations

April 6, 2026

TuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

March 31, 2026

Craig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related Cancers

March 23, 2026

TuHURA Biosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement

February 27, 2026

TuHURA Biosciences Announces Participation in Upcoming Investor Conferences

February 23, 2026

TuHURA Files Investigational New Drug Application for TBS-2025 in the Treatment of Blood-Related Cancers

February 17, 2026

TuHURA Biosciences to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

February 12, 2026

TuHURA Biosciences received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma

February 2, 2026

Decks in 2026